These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31175377)

  • 1. [Aftercare of non-muscle invasive bladder cancer].
    Schulz GB; Schlenker B; Stief CG
    Urologe A; 2019 Aug; 58(8):943-952. PubMed ID: 31175377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

  • 4. Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.
    Soorojebally Y; Neuzillet Y; Roumiguié M; Lamy PJ; Allory Y; Descotes F; Ferlicot S; Kassab-Chahmi D; Oudard S; Rébillard X; Roy C; Lebret T; Rouprêt M; Audenet F
    World J Urol; 2023 Feb; 41(2):345-359. PubMed ID: 36592175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
    Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
    Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
    Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
    BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of low-grade nonmuscle-invasive bladder cancer].
    Olbert PJ; Ohlmann CH; Schwentner C
    Urologe A; 2015 Apr; 54(4):484-90. PubMed ID: 25784271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-up procedures for non-muscle-invasive bladder cancer: an update.
    Anastasiadis A; Cordeiro E; Bus MT; Alivizatos G; de la Rosette JJ; de Reijke TM
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1229-41. PubMed ID: 23098122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Bladder and Upper Urinary Tract Follow-up Recurrence and Progression Rates of G1-2 Non-muscle-invasive Urothelial Carcinoma of the Bladder.
    Golabesk T; Palou J; Rodriguez O; Parada R; Skrobot S; Peña JA; Villavicencio H
    Urology; 2017 Feb; 100():145-150. PubMed ID: 27765584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
    Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
    BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non-muscle-Invasive Bladder Cancer.
    Feiertag N; Barry E; Abramson M; Park JY; Kovac E; Aboumohamed A; Watts K; Sankin A
    Clin Genitourin Cancer; 2023 Apr; 21(2):258-264. PubMed ID: 36621462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
    Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
    J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of semaphorin 3A in patients with urothelial cancer.
    Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
    Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
    Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
    Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [After-care of bladder carcinoma].
    Retz M; Lehmann J; Wullich B; Stöckle M
    Urologe A; 2001 Nov; 40(6):480-4. PubMed ID: 11760356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature.
    Soukup V; Babjuk M; Bellmunt J; Dalbagni G; Giannarini G; Hakenberg OW; Herr H; Lechevallier E; Ribal MJ
    Eur Urol; 2012 Aug; 62(2):290-302. PubMed ID: 22609313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
    Zuiverloon TCM; de Jong FC; Theodorescu D
    Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can urinary biomarkers replace cystoscopy?
    Maas M; Bedke J; Stenzl A; Todenhöfer T
    World J Urol; 2019 Sep; 37(9):1741-1749. PubMed ID: 30283995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.